MRNA Can't Capitalize on COVID-19 Vaccine Update

Reports that the White House could fast-track a competitor's vaccine is putting pressure on MRNA today

Digital Content Manager
Aug 24, 2020 at 10:02 AM
facebook twitter linkedin

Moderna Inc (NASDAQ:MRNA) is slipping lower this morning, down 1.9% at $62.50, despite an announcement from the biotech that enrollment levels for its late-stage 30,000-patient COVID-19 vaccine trial have exceeded 40% -- along with a potential deal with the European Union (EU). Reports that the White House could be fast tracking AstraZeneca's COVID-19 vaccine candidate could be putting pressure on MRNA today. 

From a technical standpoint,  it appears the stock's 10-day moving average has emerged as a ceiling on the charts, coming in shortly after MRNA's all-time high of $95.21 late last month. The security is losing its footing near its recently supportive 80-day moving average too, though the shares still boast a roughly 239% lead for the year. 

The brokerage bunch seems to be holding out hope for a rebound. Just three of the 13 in coverage call it a "hold," compared to 10 "buy" or better ratings. Plus, the consensus 12-month price target of $93.62 is a 40.9% premium to Friday's close. 

Option players, however, have begun changing their tune. While calls still outnumber puts at an overall basis, MRNA's 10-day put/call volume ratio of 0.53 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands higher than 91% of readings from the past year. 

Short sellers are taking interest in MRNA, too. In the last reporting period, short interest rose 10%. Now, the 27.19 million shares sold short make up 8.7% of Moderna's available float. 




Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners